Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
Vivos Therapeutics (NASDAQ: VVOS) , a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...
U.S. stocks traded higher this morning, with the Nasdaq Composite surging more than 400 points on Thursday. Following the ...
The stage is set for strong weekly wins after Wall Street's expectations for a 0.5% rate cut by the Fed shot up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback